Phase II LEAP-005 Study Antitumor Activity Results

Clinical trial data from the Phase II LEAP-005 study assessing lenvatinib plus pembrolizumab for advanced gastric, biliary tract, or pancreatic cancer. The dataset contains antitumor activity assessments per RECIST version 1.1 by Blinded Independent Central Review (BICR). It was authored by Mariano Ponz-Sarvisé and shared under a CC BY license.

Use Cases

• Analyze antitumor activity outcomes per RECIST v1.1 criteria across gastric, biliary tract, and pancreatic cancer cohorts.
• Assess response rates from the LEAP-005 trial for comparison with other advanced cancer treatments.
• Review BICR-evaluated efficacy data to support secondary research on combination immunotherapy.

Strengths

• Data originates from a structured Phase II clinical trial (LEAP-005), providing a standardized assessment framework.
• Antitumor activity is evaluated per established RECIST version 1.1 criteria by Blinded Independent Central Review (BICR).
• Shared under a permissive CC BY license, enabling reuse with attribution.

Limitations

• The dataset is very small at 13.5 KB, indicating limited scope and likely a summary table rather than patient-level data.
• No column names or sample data are provided, obscuring the specific variables and structure available for analysis.
• The data is a static snapshot from a single study, limiting generalizability to broader populations.

Provenance

Source

Phase II LEAP-005 clinical trial.

Collection Method

Clinical trial results, with antitumor activity assessed per RECIST v1.1 by Blinded Independent Central Review.

Time Range

null

Freshness

Last updated March 2026.

Geography

null